Cardiology

British Journal of General Practice

Volumn 54, Issue 506, 2004, Pages 695-702

  Fahey, Tom ^a   Schroeder, Knut ^b  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; CLOPIDOGREL; ESTROGEN; FIBRINOLYTIC AGENT; GESTAGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN;

ANGINA PECTORIS; ARTICLE; BLOOD PRESSURE MONITORING; BREAST CANCER; CARDIOLOGY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DEFIBRILLATOR; DRUG ANTAGONISM; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAPHY; HEALTH CARE PERSONNEL; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEART REHABILITATION; HUMAN; HYPERTENSION; MEDICAL DECISION MAKING; NURSE PRACTITIONER; PATIENT CARE; PATIENT REFERRAL; PRIMARY HEALTH CARE; PRIMARY PREVENTION; SECONDARY PREVENTION; STROKE; VENOUS THROMBOEMBOLISM;

CARDIOLOGY; DEFIBRILLATORS, IMPLANTABLE; HEART DISEASES; HUMANS; MYOCARDIAL REVASCULARIZATION; RISK FACTORS; RISK REDUCTION BEHAVIOR;

EID: 4544267723     PISSN: 09601643     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Grady D. Postmenopausal hormones - therapy for symptoms only. N Engl J Med 2003; 348: 1835-1837.
2. McPherson K. Where are we now with hormone replacement therapy? BMJ 2004; 328: 357-358.
3. Hays J, Ockene JK, Brunner RL, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003; 348: 1839-1854.
4. Petitti DB. Hormone replacement therapy for prevention: more evidence, more pessimism. JAMA 2002; 288: 99-101.
5. Kimmel SE, Strom BL. Giving aspirin and ibuprofen after myocardial infarction. BMJ 2003; 327: 1298-1299.
6. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003; 361: 573-574.
7. Curtis JP, Wang Y, Portnay EL, et al. Aspirin, ibuprofen, and mortality after myocardial infarction: retrospective cohort study. BMJ 2003; 327:1322-1323.
8. Ramsay LE, Haq I, Jackson PR, et al. Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table. Lancet 1996; 348: 387-388.
9. Ramsay L, Williams B, Johnston G, et al. Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens 1999; 13: 569-592.
10. Brindle P, Holt T. Cardiovascular risk assessment - time to look beyond cohort studies. Int J Epidemiol 2004; 33: 614-615.
11. Brindle P, Emberson J, Lampe F, et al. Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. BMJ 2003; 327; 1267-1270.
12. Department of Health. National service framework for coronary heart disease. London: Stationery Office, 2000.
13. Law MR, Wald NJ. Risk factor thresholds: their existence under scrutiny. BMJ 2002; 324: 1570-1576.
14. D'Agostino RB, Grundy S, Sullivan LM, Wilson P; CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001; 286: 180-187.
15. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987-1003.
16. Steel N. Thresholds for taking antihypertensive drugs in different professional and lay groups: questionnaire survey. BMJ 2000; 320: 1446-1447.
17. Devereaux P, Anderson D, Gardner MJ, et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. BMJ 2001; 323: 1218-1222.
18. Man-Son-Hing M, Laupacis A, O'Connor AM, et al. A patient decision aid regarding antithrombotic therapy for stroke prevention in atrial fibrillation: a randomised controlled trial. JAMA 1999; 282: 737-743.
19. Montgomery AA, Fahey T, Peters TJ. A factorial randomised controlled trial of decision analysis and an information video plus leaflet for newly diagnosed hypertensive patients. Br J Gen Pract 2003; 53: 446-453.
20. Clement DL, De Buyzere ML, De Bacquer DA, et al. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med 2003; 348: 2407-2415.
21. Little P, Barnett J, Barnsley L, et al. Comparison of agreement between different measures of blood pressure in primary care and daytime ambulatory blood pressure. BMJ 2002; 325: 254-259.
22. Little P, Barnett J, Barnsley L, et al. Comparison of acceptability of and preferences for different methods of measuring blood pressure in primary care. BMJ 2002; 325: 258-259.
23. Schroeder K, Fahey T, Ebrahim S. Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings. In: Cochrane Collaboration. Cochrane Library. Issue 4. Chichester, UK: John Wiley & Sons Ltd, 2004.
24. Horrocks S, Anderson E, Salisbury C. Systematic review of whether nurse practitioners working in primary care can provide equivalent care to doctors. BMJ 2002; 324: 819-823.
25. Oakeshott P, Kerry S, Austin A, Cappuccio F. Is there a role for nurse-led blood pressure management in primary care? Fam Pract 2003; 20: 469-473.
26. McHugh F, Lindsay GM, Hanlon P, et al. Nurse-led shared care for patients on the waiting list for coronary artery bypass surgery: a randomised controlled trial. Heart 2001; 86: 317-323.
27. Campbell NC, Thain J, Deans HG, et al. Secondary prevention clinics for coronary heart disease: randomised trial of effect on health. BMJ 1998; 316: 1434-1437.
28. Murchie P, Campbell NC, Ritchie LD, et al. Secondary prevention clinics for coronary heart disease: four year follow up of a randomised controlled trial in primary care. BMJ 2003; 326: 84.
29. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-1339.
30. Yusuf S, Zhao F, Mehta SR, et al; Clopidogrel in unstable angina to prevent recurrent events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation, N Engl J Med 2001; 345: 494-502.
31. Steinhubl SR, Berger PB, Mann JT, et al. Clopidogrel for the reduction of events during observation investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomised controlled trial. JAMA 2002; 288: 2411-2420.
32. Hennekens CH, Sacks FM, Tonkin A, et al. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease. Arch Intern Med 2004; 164: 40-44.
33. Kadish AH, Buxton AE, Kennedy HL, et al. ACCAHA clinical competence statement on electrocardiography and ambulatory electrocardiography. A report of the ACC/AHA/ACP-ASIM Task Forte on Clinical Competence. J Am Coll Cardiol 2001; 38: 2091-2100.
34. Sivakumaran S, Krahn AD, Klein GJ, et al. A prospective randomised comparison of loop recorders versus Holter monitors in patients with syncope or presyncope. Am J Med 2003; 115: 1-5.
35. Zimetbaum PJ, Josephson ME. The evolving role of ambulatory arrhythmia monitoring in general clinical practice. Ann Intern Med 1999; 130: 848-856.
36. Crawford MH, Bernstein SJ, Deedwania PC, et al. ACC/AHA guidelines for ambulatory electrocardiography. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the Guidelines for Ambulatory Electrocardiography). Developed in collaboration with the North American Society for Pacing and Electrophysiology. J Am Coll Cardiol 1999; 34: 912-948.
37. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998; 98: 946-952.
38. van Walraven C, Hart RG, Wells GA, et al. A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. Arch Intern Med 2003; 163: 936-943.
39. Wyse DG, Waldo AL, DiMarco JP, et al; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-1833.
40. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347: 1834-1840.
41. Falk RH. Management of atrial fibrillation - radical reform or modest modification? N Engl J Med 2002; 347: 1883-1884.
42. SPORTIF III investigators. Stroke prevention with the oral direct thrombin inhibitor Ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): a randomised controlled trial. Lancet 2003; 362: 1691-1698.
43. Verheugt F. Can we pull the plug on warfarin in atrial fibrillation? Lancet 2003; 362: 1686-1687.
44. Cooper JM, Katcher MS, Orlov MV. Implantable devices for the treatment of atrial fibrillation. N Engl J Med 2002; 346: 2062-2068.
45. Skanes AC, Krahn AD, Yee R. Progression to chronic atrial fibrillation after pacing: the Canadian trial of physiologic pacing. CTOPP investigators. J Am Coll Cardiol 2001; 38: 167-172.
46. Jolliffe JA, Rees K, Taylor RS, et al. Exercise-based rehabilitation for coronary heart disease (Cochrane Review). In: Cochrane Collaboration. Cochrane Library. Issue 3. Chichester, UK: John Wiley & Sons Ltd, 2004.
47. Ades PA. Cardiac rehabilitation and secondary prevention of coronary heart disease. N Engl J Med 2001; 345: 892-902.
48. Banzer JA, Maguire TE, Kennedy CM, et al. Results of cardiac rehabilitation in patients with diabetes mellitus. J Am Coll Cardiol 2004; 93: 81-84.
49. Schofield PM. Indications for percutaneous and surgical revascularisation: how far does the evidence base guide us? Heart 2004; 89: 565-570.
50. Steinbrüchel D, Hughes P. Primary percutaneous interventions versus fibrinolytic therapy for acute myocardial infarction (Cochrane Review). In: Cochrane Collaboration. Cochrane Library. Issue 3. Chichester, UK: John Wiley & Sons, Ltd, 2004.
51. Fox KA, Poole-Wilson PA, Henderson RA. Randomised intervention trial of unstable angina (RITA) investigators. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Lancet 2002; 360: 743-751.
52. Bhargava B, Karthikeyan G, Abizaid AS, Mehran R. New approaches to preventing restenosis. BMJ 2003; 327: 274-279.
53. Brorsson B, Bernstein SJ, Brook RH, Werkoe L; SECOR/SBU project group. Quality of life of patients with chronic stable angina before and four years after coronary revascularisation compared with a normal population. Heart 2002; 87: 140-145.
54. DiMarco JP. Medical progress: implantable cardioverter-defibrillators. N Engl J Med 2003; 349: 1836-1847.
55. Moss AS, Zareba W, Hall WJ, et al; Multicenter automatic defibrillator implantation trial II investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877-883.